Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
10.59
+0.07 (0.67%)
At close: Aug 1, 2025, 4:00 PM
10.66
+0.07 (0.66%)
After-hours: Aug 1, 2025, 5:54 PM EDT
Company Description
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies.
The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335.
Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 2, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 118 |
| CEO | Clay Siegall |
Contact Details
Address: 18702 North Creek Parkway, Suite 100 Bothell, Washington 98011 United States | |
| Phone | 425 939 7410 |
| Website | immunome.com |
Stock Details
| Ticker Symbol | IMNM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001472012 |
| CUSIP Number | 45257U108 |
| ISIN Number | US45257U1088 |
| Employer ID | 77-0694340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Clay B. Siegall Ph.D. | Chairman, President and Chief Executive Officer |
| Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel and Corporate Secretary |
| Kinney Horn | Chief Business Officer |
| Max Rosett | Chief Financial Officer |
| Dr. Philip Tsai | Chief Technical Officer |
| Dr. Jack Higgins Ph.D. | Chief Scientific Officer |
| Dr. Robert J. Lechleider M.D. | Chief Medical Officer |
| Roee Shahar | Executive Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jun 11, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |